切换至 "中华医学电子期刊资源库"
高级检索
中华眼科医学杂志(电子版)

中华眼科医学杂志(电子版) ›› 2020, Vol. 10 ›› Issue (02) : 103 -109. doi: 10.3877/cma.j.issn.2095-2007.2020.02.007

论著

三种非甾体抗炎药物在超声乳化白内障吸除联合人工晶状体植入术围手术期的应用研究
李妍1, 陈佩卿1,†(), 陈子和1, 徐佳1, 陶永钢1   
  1. 1. 310000　杭州，浙江大学医学院附属第二医院眼科中心
  • 收稿日期:2020-03-02 出版日期:2020-04-28
  • 通信作者: 陈佩卿
  • 基金资助:
    国家自然科学基金项目(81700815)

Clinical study of three non-steroidal anti-inflammatory drugs in the perioperative period of phacoemulsification surgery

Yan Li1, Peiqing Chen1,†(), Zihe Chen1, Jia Xu1, Yonggang Tao1   

  1. 1. Eye Center of the second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310000, China
  • Received:2020-03-02 Published:2020-04-28
  • Corresponding author: Peiqing Chen
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李妍, 陈佩卿, 陈子和, 徐佳, 陶永钢. 三种非甾体抗炎药物在超声乳化白内障吸除联合人工晶状体植入术围手术期的应用研究[J]. 中华眼科医学杂志(电子版), 2020, 10(02): 103-109.

Yan Li, Peiqing Chen, Zihe Chen, Jia Xu, Yonggang Tao. Clinical study of three non-steroidal anti-inflammatory drugs in the perioperative period of phacoemulsification surgery[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2020, 10(02): 103-109.

目的

探讨三种非甾体抗炎药物在超声乳化白内障吸除联合人工晶状体植入术围手术期的疗效。

方法

选取2018年7月至2019年1月于浙江大学医学院附属第二医院眼科就诊并行白内障手术的患者122例(122只眼)进行研究。其中，男性36例(36只眼)，女性86例(86只眼)；年龄50~85岁，平均年龄(68.2±10.2)岁。采用数字表法将患者随机分为A组、B组及C组。全部行超声乳化白内障吸除联合人工晶状体植入术，并在围手术期分别滴用0.1%普拉洛芬滴眼液、0.1%溴芬酸钠滴眼液及0.1%双氯芬酸钠滴眼液。患者年龄、超声乳化能量及有效超声乳化时间采用(±s)描述，组间比较采用单因素方差分析。患者眼压、前房闪辉、角膜中央厚度、术后干眼情况及自觉症状评分采用(±s)描述，组间比较采用两因素重复测量方差分析。术后自觉症状重度患者的发生率采用眼数和百分比表示，并进行χ2检验。

结果

A组、B组及C组患者的眼压，术前分别为(13.55±2.88)mmHg(1 mmHg＝0.133 kPa)、(13.16±3.71)mmHg及(13.83±2.74)mmHg；术后1 d分别为(15.21±3.71)mmHg、(14.46±4.78)mmHg及(14.73±4.04)mmHg；术后7 d分别为(14.19±3.34)mmHg、(13.66±3.46)mmHg及(14.56±3.65)mmHg；术后30 d分别为(12.68±2.69)mmHg、(12.16±3.65)mmHg及(12.89±3.17)mmHg，三组患者术前、术后1 d、术后7 d及术后30 d的差异均无统计学意义(F＝0.49，0.12，0.65，0.59；P>0.05)。A组、B组及C组患者的前房闪辉值，术前分别为(6.09±2.98)pc/ms、(6.81±2.93)pc/ms及(7.31±5.87)pc/ms；术后1 d分别为(13.04±6.92)pc/ms、(12.72±11.53)pc/ms及(14.22±11.31)pc/ms；术后7 d分别为(7.77±3.73)pc/ms、(6.99±4.19)pc/ms及(8.14±3.15)pc/ms；术后30 d分别为(7.06±3.72)pc/ms、(8.21±3.16)pc/ms及(9.29±4.97)pc/ms，三组患者术前、术后1 d、术后7 d及术后30 d的差异均无统计学意义(F＝0.90，0.25，0.97，2.99；P>0.05)。A组、B组及C组患者的角膜中央厚度，术前分别为(536.05±30.07)μm、(537.08±30.08)μm及(523.14±38.65)μm；术后1 d分别为(628.91±84.20)μm、(674.94±154.43)μm及(619.02±144.65)μm；术后7 d分别为(550.59±38.64)μm、(553.14±35.43)μm及(543.31±45.51)μm；术后30 d分别为(539.93±33.98)μm、(549.27±34.14)μm及(527.78±78.74)μm，三组患者术前、术后1 d、术后7 d及术后30 d的差异均无统计学意义(F＝2.22，2.02，0.64，1.45；P >0.05)。A组、B组及C组患者的泪河高度，术前分别为(0.18±0.08)mm、(0.21±0.11)mm及(0.22±0.09)mm；术后7 d分别为(0.19±0.08)mm、(0.19±0.08)mm及(0.25±0.15)mm；术后30 d分别为(0.22±0.11)mm、(0.23±0.12)mm及(0.24±0.15)mm，三组患者术后7 d的差异有统计学意义(F＝4.97；P<0.05)。A组、B组及C组患者的自觉症状评分，术后7 d分别为(1.95±2.39)、(2.19±2.54)及(1.45±1.25)分；术后30 d分别为(2.33±2.03)、(1.73±2.02)及(1.51±2.02)分，三组患者术后7 d及术后30 d的差异无统计学意义(F＝1.27，1.74；P>0.05)。A组、B组及C组患者的自觉症状评分≥3分(重度)者的占比，术后7 d分别为20.5%、38.9%及21.4%；术后30 d分别为38.6%、25.0%及16.7%，三组患者术后7 d及30 d的差异有统计学意义(χ2＝218.45，160.82；P<0.05)。

结论

三组非甾体类抗炎药物在白内障超声乳化手术围手术期应用的抗炎效果相同；C组药物对缓解白内障术后干眼的作用优于A组和B组。C组患者术后自觉症状评分优于其他两组。

关键词: 非甾体类抗炎药, 白内障超声乳化手术, 眼压, 房水闪辉, 干眼
Objective

The aim of this study was to explore the effect of three non steroidal anti-inflammatory drugs in the perioperative period of phacoemulsification combined with intraocular lens implantation.

Methods

From July 2018 to January 2019, 122 patients (122 eyes) with cataract surgery in Eye Center of the Second Affiliated Hospital, Zhejiang University Medical College were selected. Among them, 36 cases (36 eyes) were male, 86 cases (86 eyes) were female, and the average age was (68.2±10.2) years-old. The patients were randomly divided into A group, B group and C group. All patients were underwent phacoemulsification combined with intraocular lens implantation, and 0.1% pramiphene eye drops, 0.1% sodium bromfenate eye drops and 0.1% diclofenac sodium eye drops were used in the perioperative period. The age, phacoemulsification energy and effective phacoemulsification time of patients were described by(±s), and one-way ANOVA was used for comparison between groups. The scores of intraocular pressure, anterior chamber flash, central corneal thickness, postoperative dry eye condition and conscious symptoms were described by(±s) and ANOVA. The incidence of severe postoperative symptoms was expressed by the number and percentage, and the chi-square test was performed.

Results

Intraocular pressure of all groups before operation were (13.55±2.88) mmHg (1 mmHg=0.133 kPa), (13.16±3.71) mmHg and (13.83±2.74) mmHg; 1 d after operation, they were (15.21±3.71) mmHg, (14.46±4.78) mmHg and (14.73±4.04) mmHg, respectively; 7 d after operation, they were (14.19±3.34) mmHg, (13.66±3.46) mmHg and (14.56±3.65) mmHg, respectively; 30 d after operation, they were (12.68±2.69) mmHg, (12.16±3.65) mmHg and (12.89±3.17) mmHg, respectively. There was no significant difference among three groups before operation, 1 d after operation, 7 d after operation and 30 d after operation (F=0.49, 0.12, 0.65, 0.59; P>0.05). All patients′ anterior chamber flash value before operation were (6.09±2.98) pc/ms, (6.81±2.93) pc/ms and (7.31±5.87) pc/ms, respectively; 1 d after operation, they were (13.04±6.92) pc/ms, (12.72±11.53) pc/ms and (14.22±11.31) pc/ms, respectively; 7d after operation, they were (7.77±3.73) pc/ms, (6.99±4.19) pc/ms and (8.14±3.15) pc/ms, respectively; 30 d after operation, they were (7.06±3.72) pc/ms, (8.21±3.16) pc/ms and (9.29±4.97) pc/ms, respectively. There was no significant difference among three groups before operation, 1 d, 7 d and 30 d after operation (F=0.90, 0.25, 0.97, 2.99; P>0.05). The central corneal thickness of all patients before operation were (536.05±30.07) μm, (537.08±30.08) μm and (523.14±38.65) μm, respectively; 1 d after operation, they were (628.91±84.20) μm, (674.94±154.43) μm and (619.02±144.65) μm, and 7 d after operation, they were (550.59±38.64) μm, (553.14±35.43) μm and (543.31±45.51) μm, respectively; 30 d after operation, they were (539.93±33.98) μm, (549.27±34.14) μm and (527.78±78.74) μm, respectively. There was no significant difference among three groups before operation, 1 d, 7 d and 30 d after operation (F=2.22, 2.02, 0.64, 1.45; P>0.05). The height of lacrimal river in all groups before operation were (0.18±0.08) mm, (0.21±0.11) mm and (0.22±0.09) mm, respectively; 7 d after operation, they were (0.19±0.08) mm, (0.19±0.08) mm and (0.25±0.15) mm, respectively; 30 d after the operation, they were (0.22±0.11) mm, (0.23±0.12) mm and (0.24±0.15) mm, respectively. The difference of 7 d after operation was statistically significant (F=4.97, P<0.05). The scores of conscious symptoms in 3 groups 7 d after operation were (1.95±2.39), (2.19±2.54) and (1.45±1.25), respectively; 30 d after operation, those were (2.33±2.03), (1.73±2.02) and (1.51±2.02), respectively. There was no significant difference between three groups in 7 d and 30 d after operation (F=1.27, 1.74; P>0.05). The proportion of patients in 3 groups with severe (scores≥3), 7 d after operation, 20.5%, 38.9% and 21.4%, respectively; 30 d after operation, 38.6%, 25.0% and 16.7%, respectively. There was a significant difference between three groups in 7 d and 30 d after operation (χ2=218.45, 160.82; P<0.05).

Conclusions

Three groups of non steroidal anti-inflammatory drugs have the same anti-inflammatory effect in the perioperative period of cataract phacoemulsification; C group was better than others in relieving dry eyes after cataract surgery. The score of postoperative conscious symptoms in C group was better than other groups.

Key words: Non-steroidal anti-inflammatory drugs, Phacoemulsification, Intraocular pressure, Flash of aqueous humor, Dry eye
表1 纳入本研究三组患者一般情况的比较
组别 例数 年龄(岁) 男性/女性 超声乳化能量(%) 有效超声时间(s)
A组 44 67.7± 9.2 12/32 15.34±6.34 5.12±4.14
B组 36 69.9±10.6 10/26 15.89±7.36 4.78±3.88
C组 42 67.2±10.9 14/28 14.19±8.57 4.29±3.63
χ2/F值   0.77* 0.45** 0.54* 0.47*
P值   >0.05 >0.05 >0.05 >0.05
表2 不同时间点三组患者眼压的比较(±s ，mmHg)
组别 例数 术前 术后1 d 术后7 d 术后30 d
A组 44 13.55±2.88 15.21±3.71 14.19±3.34 12.68±2.69
B组 36 13.16±3.71 14.46±4.78 13.66±3.46 12.16±3.65
C组 42 13.83±2.74 14.73±4.04 14.56±3.65 12.89±3.17
F值   0.49 0.12 0.65 0.59
P值   >0.05 >0.05 >0.05 >0.05
表3 不同时间点三组患者前房闪辉的比较(±s，pc/ms)
组别 例数 术前 术后1 d 术后7 d 术后30 d
A组 44 6.09±2.98 13.04± 6.92 7.77±3.73 7.06±3.72
B组 36 6.81±2.93 12.72±11.53 6.99±4.19 8.21±3.16
C组 42 7.31±5.87 14.22±11.31 8.14±3.15 9.29±4.97
F值   0.90 0.25 0.97 2.99
P值   >0.05 >0.05 >0.05 >0.05
表4 不同时间点三组患者角膜中央厚度的比较(±s，μm)
组别 例数 术前 术后1 d 术后7 d 术后30 d
A组 44 536.05±30.07 628.91± 84.20 550.59±38.64 539.93±33.98
B组 36 537.08±30.08 674.94±154.43 553.14±35.43 549.27±34.14
C组 42 523.14±38.65 619.02±144.65 543.31±45.51 527.78±78.74
F值   2.22 2.02 0.64 1.45
P值   >0.05 >0.05 >0.05 >0.05
表5 不同时间点三组患者干眼常规检查结果的比较(±s)
组别 例数 泪河高度(mm) 角膜荧光染色(分)
术前 术后7 d 术后30 d 术后7 d 术后30 d
A组 44 0.18±0.08 0.19±0.08 0.22±0.11 0.68±1.49 0.16±0.48
B组 36 0.21±0.11 0.19±0.08 0.23±0.12 0.19±0.47 0.03±0.17
C组 42 0.22±0.09 0.25±0.15 0.24±0.15 0.54±1.42 0.19±0.62
F值   2.98 4.97 0.34 1.56 1.13
P值   >0.05 <0.05 >0.05 >0.05 >0.05
图2 三组患者术后自觉症状评分重度所占人数比例的比较
[1]
Penny AA, Ivo D, Joel M, et al. Age-related Cataract Lancet[J], 2005, 365(9459): 599-609 .
[2]
Stürrmer J. Cataracts-Trend and New Developments[J]. Ther Umsch, 2009, 66(3): 167-71.
[3]
朱光辉，王奇志，蔡彩琴，等. 非甾体类抗炎药在眼科中的应用研究进展[J]. 眼视光学杂志，2009，11(2): 157-160.
[4]
陈馨. 非甾体类抗炎药在眼科围手术期的应用分析[J]. 中医临床研究，2013，5(12)：99-100.
[5]
刘晖，刘刚，罗莉丽. 白内障术后联用激素和非甾体类抗炎药的临床效果考察[J]. 当代医学，2017，23(11)：16-17.
[6]
秦岭. 在眼科临床上应用非甾体类抗炎药的新进展[J]. 当代医药论丛，2016，14(7)：118-119.
[7]
马文新，唐由之. 晶体分期分级的研究现状[J]. 中国中医眼科杂志，1997，7(2)：120-123.
[8]
姚克. 微小切口白内障手术学[M]. 1版，北京，科学技术出版社，2012：5-7.
[9]
Liu YC, Wilkins M, Kim T, et al. cataracts[J]. Lancet, 2017, 390(10094): 600-612.
[10]
Handayani N, Permatasari N, Sujuti H, et al. Effect of GSH and niacin combination on protein oxidation, ER stress, glycation and aggregation in HLE cells under high glucose condition[J]. 国际眼科杂志，2020, 20(1): 4-8.
[11]
Nartey A. The pathophysiology of cataract and major interventins to retarding its progression: a mini review[J]. Adv Ophthalmol Vis Syst, 2017, 6(3): 178.
[12]
Srinivas M. Delivery of glutathione to the lens nucleus[J]. J Ophthalmic Vis Res, 2014, 9(1): 148-149.
[13]
Zheng SJ. High-dose supplements of vitamins C and E, low-dose multivitamins, and the risk of age-related cataract: a population-based prospective cohort study of men[J]. Am J Epidemiol, 2013, 177(6): 548-555.
[14]
姜玟彤，刘平. 年龄相关性白内障防治药物的相关研究进展[J]. 国际眼科杂志，2017, 17(2)：243-246.
[15]
Chung JK, Hyung KL, Mee KK, et al. Cataract Surgery Practices in the Republic of Korea: A Survey of the Korean Society of Cataract and Refractive Surgery 2018[J]. Korean J Ophthalmol, 2019, 33(5): 451-457.
[16]
Burde RM, Waltman SR. Topical corticosteroids after cataract surgery[J]. Ann Ophthalmol, 1972, 4(4): 290-293.
[17]
Kim SJ, Flach AJ, Jampol LM, et al. Nonsteroidal antiin ammatory drugs in ophthalmology[J]．Survey of Ophthalmology，vol. 2010，55(2) ：108-133.
[18]
Colin J. The role of NSAIDs in the management of postop erative ophthalmic inflammation[J]. Drugs, 2007, 67：1291-1308.
[19]
Juthani VV, Clearfield E, Chuck RS. Anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery[J]. Cochrane Database Syst Rev, 2017, 7(7): CD010516.
[20]
Cañadas C, Alvarado H, Calpena AC, et al. In vitro, ex vivo and in vivo characterization of PLGA nanoparticles loading pranoprofen for ocular administration[J]. Int J Pharm, 2016, 511(2): 719-727.
[21]
Abrego G, Alvarado HL, Egea MA, et al. Design of nanosuspensions and freeze-dried PLGA nanoparticles as a novel approach for ophthalmic delivery of pranoprofen[J]. J Pharm Sci, 2014, 103(10): 3153-3164.
[22]
冯江松，张进，杨莉，等. 普拉洛芬联合妥布霉素地塞米松滴眼液在白内障摘除术后的应用效果[J]. 国际眼科杂志，2017, 17(19)：1759-1761.
[23]
Jong SL, Young HK, Young MP. The Toxicity of Nonsteroidal Anti-inflammatory Eye Drops Against Human Corneal Epithelial Cells in VitroJ Korean Med Sci[J]. 2015, 30(12): 1856-1864.
[24]
沈歆雪，肖启国. 非甾体类抗炎药在非感染性眼表炎症性疾病中的应用及进展[J]. 现代医药卫生，2017，33(9)：1327-1329.
[25]
Duan P, Liu Y, Li JW. The Comparative Efficacy and Safety of Topical Non-Steroidal Anti-Inflammatory Drugs for the Treatment of Anterior Chamber Inflammation After Cataract Surgery: A Systematic Review and Network Meta-Analysis[J]. Graefes Arch Clin Exp Ophthalmol, 2017, 255 (4): 639-649.
[26]
赵向阳，伊琼，李卫平. 安贺拉滴眼液在LASEK中的应用[J]. 实用诊断与治疗杂志，2005，19(7)：494-495.
[27]
Donnenfeld ED, Perry HD, Wittpenn JR, et al. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve[J]. J Cataract Refract Surg, 2006, 32(9): 1474-1482.
[28]
Sahu S, Ram J, Bansal R, et al. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laserflare photometry in patients having phacoemulsification[J]. J Cataract Refract Surg, 2015, 41 (10): 2043-2048.
[29]
Sarkar S, Mondal KK, Roy SS, et al. Comparison of preoperative nepafenac(0.1%) and flurbiprofen(0.03%)eye drops in maintaining mydriasis during small incision cataract surgery in patients with senile cataract: A randomized, double-blind study[J]. Indian J Pharmacol, 2015, 47(5): 491-495.
[30]
Zhao XY, Song X, Wang EQ, et al. Comparison of the Efficacy and Patients' Tolerability of Nepafenac and Ketorolac in the Treatment of Ocular Inflammation Following Cataract Surgery: A Meta-Analysis of Randomized Controlled Trials[J]. PLoS One, 2017, 12(3): e0173254.
[31]
Nuraita I, Gunawan W, Ekantini R, et al. 双氯芬酸与奈帕芬胺在白内障术后抗炎疗效比较. 国际眼科杂志，2019，19(5) ：719-723.
[32]
Wang XJ, Wong SH, Givergis R, et al. Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK[J]. Clin Ophthalmol, 2011, 5: 1451-1457.
[33]
国家药典委员会. 中华人民共和国药典(2005 年版2 部)[M]. 北京：化学工业出版社，2005，附录：22-30.
[34]
Donnenfeld ED, Holland EJ, Stewart RH, et al. Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation[J]. Ophthalmology, 2007, 114(9): 1653-1662.
[35]
Carreno E, Portero A, Galarreta DJ, et al. Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction[J]. Clin Ophthalmol, 2012, 6: 637-644.
[36]
Malik A, Sadafale A, Gupta YK, et al. A comparative study of various topical nonsteroidal anti-inflammatory drugs to steroid drops for control of post cataract surgery inflammation[J]. Oman J Ophthalmol, 2016, 9(3): 150-156.
[37]
Kim SJ, Schoenberger SD, Thorne JE, et al. Topical Nonst eroidal Anti-inflammatory Drugs and Cataract Surgery: A Report by the American Academy of Ophthalmology[J]. Ophthalmology, 2015, 122(11): 2159-2168.
[38]
李晓鹏，李彦，焦军杰，等. 白内障超声乳化对泪膜功能的影响[J]. 国际眼科杂志，2015，15(4)：669-671.
[39]
陆博，张劲松. 人工泪液对年龄相关性白内障术后患者泪膜的影响[J]. 国际眼科杂志，2007，7(4)：1006-1008.
[40]
李骏，晏晓明. 苯扎氯胺对体外培养的人角膜上皮细胞毒性作用的研究[J]. 眼科研究，2008，26(11)：814-817.
[41]
黄洁，唐建明，赵婕，等. 白内障超声乳化患者术前及术后患者干眼症状研究[J]. 中国实用眼科杂志，2015，33(13)：74-76.
[42]
王欣，赵峰，徐建江，等. 双氯芬酸钠透明质酸钠滴眼液治疗急性变态反应性结膜炎评价[J]. 中国实用眼科杂志，2010，28(4)：339-343.
[1] 曾舒涵, 庾楠楠, 应道静, 陈丽植, 容丽萍, 莫樱, 蒋小云. 激素敏感型原发性肾病综合征患儿激素治疗巩固维持阶段不同减量方案比较[J]. 中华妇幼临床医学杂志(电子版), 2022, 18(04): 468-475.
[2] 王胜男, 孙挥宇, 接英, 谢雯, 毛菲菲, 李丹, 鲁丹, 刘夕瑶. 慢性丙型肝炎患者干眼临床特征[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(01): 48-54.
[3] 孙艳华. 围绝经期干眼患者结膜上皮细胞中miR-146a、TRAF6的表达研究[J]. 中华细胞与干细胞杂志(电子版), 2021, 11(05): 279-283.
[4] 冷玥祺, 廖衍沣, 武歆纯, 李美瑶, 石逸雯, 王晋豪, 杨嘉瑞, 李学民. 环境因素对眼部生理与病理影响的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(02): 109-113.
[5] 李茹月, 庞睿奇, 王宁利. 血脂异常与原发性开角型青光眼发病相关性的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(01): 35-39.
[6] 白静怡, 黄轩, 张益权, 田颖, 陶勇. 小鼠干眼模型构建及其角膜特征检测的实验研究[J]. 中华眼科医学杂志(电子版), 2023, 13(01): 12-17.
[7] 荆大兰, 江晓丹, 杨嘉瑞, 李学民. 眼表菌群改变与干眼关系的研究进展[J]. 中华眼科医学杂志(电子版), 2022, 12(06): 372-376.
[8] 王柠, 王佳伟, 刘旭阳. 重视眼颅压力差在多学科领域的应用[J]. 中华眼科医学杂志(电子版), 2022, 12(06): 321-325.
[9] 程英, 安文在, 林丹婷, 王宁利. 肠道菌群与眼部常见疾病关系的研究进展[J]. 中华眼科医学杂志(电子版), 2022, 12(05): 305-309.
[10] 丁一, 郝然, 王嘉瑢, 李学民. 角膜神经改变与干眼的研究进展[J]. 中华眼科医学杂志(电子版), 2022, 12(04): 242-246.
[11] 师宜鹏, 孙文英, 谢立科, 解晓斌. 选择性激光小梁成形术的研究进展[J]. 中华眼科医学杂志(电子版), 2022, 12(04): 237-241.
[12] 雷蕊莲, 赵军梅, 唐桂兰. 微导管辅助微创青光眼手术研究的新进展[J]. 中华眼科医学杂志(电子版), 2022, 12(03): 178-182.
[13] 黄瑶, 邵蕾, 杨婧研, 李培, 魏文斌. 玻璃体腔注药术后早期眼压测量必要性的临床研究[J]. 中华眼科医学杂志(电子版), 2021, 11(06): 353-358.
[14] 王静漪, 接英. 泪液渗透压在干眼发生机制和临床应用中的研究进展[J]. 中华眼科医学杂志(电子版), 2021, 11(05): 301-305.
[15] 马铭绅, 范懿, 李月月, 苏帆, 杨新吉. 甲状腺相关眼病继发性高眼压和青光眼发病机制与治疗的研究进展[J]. 中华眼科医学杂志(电子版), 2020, 10(06): 380-384.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号